Analyst puts NPS Pharma under microscope

The Motley Fool examines the travails at NPS Pharmaceuticals, which saw shares plunge from close to $50 to $4 as it struggled to gain an approval for its osteoporosis drug Preos. According to SEC documents, NPS needs a partner to help fund the next study of Preos. But it's been whacking employees, sold its HQ facility and struck a royalty deal on another drug as it staggers under a heavy debt load. All is not lost, though, sayeth the Fool. Teduglutide is in a late-stage trial for short bowel syndrome and there's a pretty good pipeline of candidates that can create some real opportunities.

- here's the view from The Motley Fool

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.